✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Glaxosmithkline Pharmaceuticals Ltd.

GLAXO

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹43,900 Cr.
P/E
45.96

Glaxosmithkline Pharmaceuticals Ltd.

  • Glaxosmithkline Phar
  • Ipca Laboratories
  • Ajanta Pharma
  • TJI Pharma

FAQs on Glaxosmithkline Pharmaceuticals Ltd. Shareprice

Glaxosmithkline Phar has given lower returns compared to its competitors.
Glaxosmithkline Phar has grown at ~10.55% over the last 5yrs while peers have grown at a median rate of 15.02%

Glaxosmithkline Phar is not expensive.
Latest PE of Glaxosmithkline Phar is 45.4, while 3 year average PE is 47.34.
Also latest EV/EBITDA of Glaxosmithkline Phar is 35.16 while 3yr average is 35.62.

View FAQ's On Business

Growth Table

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Ipca Laboratories
  • Ajanta Pharma

Balance Sheet

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Ipca Laboratories
  • Ajanta Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Ipca Laboratories
  • Ajanta Pharma

Cash Flow

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Ipca Laboratories
  • Ajanta Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Ipca Laboratories
  • Ajanta Pharma

Quarterly Results

  • Glaxosmithkline Pharmaceuticals Ltd.
  • Ipca Laboratories
  • Ajanta Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Glaxosmithkline Pharmaceuticals Ltd. Financials

Balance sheet of Glaxosmithkline Phar is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Glaxosmithkline Phar is increasing.
Latest net debt of Glaxosmithkline Phar is -₹747.83 Crs as of Sep-25.
This is greater than Mar-25 when it was -₹2,807.03 Crs.

Yes, profit is increasing.
The profit of Glaxosmithkline Phar is ₹955 Crs for TTM, ₹928 Crs for Mar 2025 and ₹590 Crs for Mar 2024.

The company seems to pay a good stable dividend.
Glaxosmithkline Phar latest dividend payout ratio is 98.62% and 3yr average dividend payout ratio is 93.09%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech